Effects of subthalamic nucleus deep brain stimulation on the neuropsychological function of patients with Parkinson's disease: A meta-analysis
郑文韬,欧阳佳,许可,苗泽宇,刘如恩
DOI: https://doi.org/10.3760/cma.j.cn112050-20191228-00546
2020-01-01
Abstract:Objective:To comprehensively evaluate the effects of subthalamic nucleus deep brain stimulation (STN-DBS) on the neuropsychological function of patients with Parkinson′s disease (PD) with meta analysis.Methods:Randomized controlled trials (RCTs) of STN-DBS for PD were retrieved from PubMed, Embase, Cochrane library, CNKI, WanFang, VIP from the establishment of the databases to December 1st, 2019 using the following key words: subthalamic nucleus, STN, deep brain stimulation, DBS, Parkinson disease, neuropsychological. The Jadad scale was applied to evaluate the quality of the studies. Meta-analysis was performed using the software of Revman 5.3 to evaluate the effects of STN-DBS on the neuropsychological function in patients with PD.Results:A total of 5 studies with Jadad score≥4 involving 740 PD patients were included. Meta-analysis showed that compared with those receiving drug therapy alone, patients undergoing STN-DBS had significantly better results in terms of the Beck Depression Inventory scores (
SMD=-0.27, 95%
CI: -0.47-0.06,
P=0.010). In contrast, STN-DBS significantly reduced the scores of verbal fluency (phonemic fluency:
SMD=-0.44, 95%
CI: -0.63-0.25,
P<0.001; semantic fluency:
SMD=-0.29, 95%
CI: -0.47-0.10,
P=0.002). There were no significant differences between pre- and post-treatment according to the indexes including Mattis Dementia Rating Scale (MDRS), Wechsler Adult Intelligence Scale (WAIS) Digit Span, Wisconsin Card Sorting Test (WCST), Trail Making Test Part A (TMT-A), Boston Naming Test (BNT) in both groups (MDRS:
SMD=0.03, 95%
CI: -0.15-0.21,
P=0.72; WAIS Digit Span forward:
SMD=0.06, 95%
CI: -0.16-0.28,
P=0.61; WAIS Digit Span backward:
SMD=-0.14, 95%
CI: -0.36-0.08,
P=0.21; WCST categories achieved:
SMD=-0.23, 95%
CI: -0.57-0.11,
P=0.19; TMT-A:
SMD=-0.08, 95%
CI: -0.31-0.15,
P=0.50; Boston Naming Test:
SMD=-0.03, 95%
CI: -0.29-0.24,
P=0.85).
Conclusions:STN-DBS may improve the depressive symptoms of patients with PD without affecting the overall cognitive function. However, there seems to be postoperative decline of verbal fluency.